Large drug companies built in-house expertise for navigating FDA regulation, and this regulatory know-how acts as a barrier that keeps small biotech companies out, funneling drug development into large firms.
causalpending
Speaker
Sam PeltzmanEvidence Quote
“it keeps out small companies and it basically forces all drug development into these larger companies”
Created: 11/11/2026, 5:13:30 AM
Your notes
Loading notes...